Form 4 for VIR Vir Biotechnology, Inc.
Accepted 2022-02-24 00:00:00 ET · period of report 2022-02-22 · accession 0001209191-22-012954 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-02-24 | 2022-02-22 | VIR | Pang Phillip | Chief Medical Off | A - Grant | $0.00 | +67.0K | 156.8K | +75% | $0 |
| D | 2022-02-24 | 2022-02-22 | VIR | Pang Phillip | Chief Medical Off | A - Grant | $0.00 | +64.0K | 64.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-02-22 | A | A | 67,000 | $0.00 | 156,768 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2022-02-22 | A | A | 64,000 | $0.00 | 64,000 | D | $29.48 · — to 2032-02-21 | 64,000 Common Stock | (F2) 25% of the shares subject to the stock option vest and become exercisable on February 22, 2023, and the remainder vest in 36 equal monthly installments thereafter. |